+

WO1998015635A3 - Treatment of cancer using a recombinant poxvirus containing a nucleic acid sequence encoding a cytokine - Google Patents

Treatment of cancer using a recombinant poxvirus containing a nucleic acid sequence encoding a cytokine Download PDF

Info

Publication number
WO1998015635A3
WO1998015635A3 PCT/CA1997/000729 CA9700729W WO9815635A3 WO 1998015635 A3 WO1998015635 A3 WO 1998015635A3 CA 9700729 W CA9700729 W CA 9700729W WO 9815635 A3 WO9815635 A3 WO 9815635A3
Authority
WO
WIPO (PCT)
Prior art keywords
cells
cytokine
nucleic acid
virus
cancer
Prior art date
Application number
PCT/CA1997/000729
Other languages
French (fr)
Other versions
WO1998015635A2 (en
Inventor
Diane M Gajewczyk
James Tartaglia
B Cox
J Alexander
M C Bonnet
I Diaz
B Cornet
E Paoletti
Michel H Klein
Original Assignee
Connaught Lab
Virogenetics Corp
Diane M Gajewczyk
James Tartaglia
B Cox
J Alexander
M C Bonnet
I Diaz
B Cornet
E Paoletti
Michel H Klein
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Connaught Lab, Virogenetics Corp, Diane M Gajewczyk, James Tartaglia, B Cox, J Alexander, M C Bonnet, I Diaz, B Cornet, E Paoletti, Michel H Klein filed Critical Connaught Lab
Priority to AU44485/97A priority Critical patent/AU4448597A/en
Publication of WO1998015635A2 publication Critical patent/WO1998015635A2/en
Publication of WO1998015635A3 publication Critical patent/WO1998015635A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Recombinant pox virus, specifically an avipox virus, preferably a canarypox virus, having therein a nucleic acid molecule encoding a biological response modifier, specifically a cytokine or chemokine, or immunomodulating fragment thereof, in a non-essential region of the recombinant virus genome transfect cells to express the biological immune response modifier. The transfected cells are used to treat cancer by intratumor administration of by in vivo treatment of tumor cells and reintroduction of the treated tumor cells. The cells also are used, in a non-replicating form, to protect a host against tumor formation.
PCT/CA1997/000729 1996-10-04 1997-10-03 Treatment of cancer using a recombinant poxvirus containing a nucleic acid sequence encoding a cytokine WO1998015635A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU44485/97A AU4448597A (en) 1996-10-04 1997-10-03 Treatment of cancer using a recombinant poxvirus containing nucleic acid sequence encoding a cytokine

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2753096P 1996-10-04 1996-10-04
US60/027,530 1996-10-04

Publications (2)

Publication Number Publication Date
WO1998015635A2 WO1998015635A2 (en) 1998-04-16
WO1998015635A3 true WO1998015635A3 (en) 1998-07-09

Family

ID=21838268

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA1997/000729 WO1998015635A2 (en) 1996-10-04 1997-10-03 Treatment of cancer using a recombinant poxvirus containing a nucleic acid sequence encoding a cytokine

Country Status (2)

Country Link
AU (1) AU4448597A (en)
WO (1) WO1998015635A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999053036A2 (en) 1998-04-14 1999-10-21 Sugen, Inc. Ste20-related protein kinases
CA2412050C (en) * 2000-06-15 2011-03-22 Jeffrey Schlom A recombinant non-replicating virus expressing gm-csf and uses thereof to enhance immune responses

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994016716A1 (en) * 1993-01-21 1994-08-04 Virogenetics Corporation Recombinant virus immunotherapy

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994016716A1 (en) * 1993-01-21 1994-08-04 Virogenetics Corporation Recombinant virus immunotherapy

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
90TH ANNUAL MEETING OF THE AMERICAN UROLOGICAL ASSOCIATION, 23 April 1995 (1995-04-23) - 28 April 1995 (1995-04-28), LAS VEGAS, USA, XP002062562 *
91ST AANUAL MEETING OF THE AMERICAN UROLOGY ASSOCIATION, no. 5, 4 May 1996 (1996-05-04) - 9 May 1996 (1996-05-09), ORLANDO, FLORIDA, USA, XP002062560 *
91ST ANNUAL MEETING OF THE AMERICAN UROLOGY ASSOCIATION, 4 May 1996 (1996-05-04) - 9 May 1996 (1996-05-09), ORLANDO , FLORIDA,USA, XP002062561 *
BRAMSON J: "IMMUNOTHERAPY OF MURINE BREAST CANCER USING AN ADENOVIRUS VECTOR EXPRESSING INTERLEUKIN-12", PROCEEDINGS OF THE 87TH. ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, WASHINGTON, APR. 20 - 24, 1996, no. MEETING 87, 1 March 1996 (1996-03-01), AMERICAN ASSOCIATION FOR CANCER RESEARCH, pages 341, XP000574942 *
G.S. RAO ET AL: "Canary pox (ALVAC) virus mediated cytokine gene therapy induces tumor specific immunity against mouse bladder tumor", JOURNAL OF UROLOGY, vol. 155, no. 5suppl., May 1996 (1996-05-01), pages 570A *
I. PUISIEUX ET AL: "Curative and protective effects against murine tumors by iL-12 gene therapy using a canary pox virus vector", CANCER GENE THERAPY, vol. 4, no. 6 conf. suppl., November 1997 (1997-11-01), pages S53 *
M. KAWAKITA ET AL: "Canary pox (ALVAC) virus-mediated cytokinegene therapy induces tumor specific and non-specific immunity against mouse prostate tumor", JOURNAL OF UROLOGY, vol. 155, no. 5 suppl., May 1996 (1996-05-01), pages 516A *
M. KAWAKITA ET AL: "Effect of canary-pox (ALVAC) virus-mediated cytokine gene expression on prostate tumor growth", JOURNAL OF UROLOGY, vol. 153, no. 4, April 1995 (1995-04-01), pages 469A *
M. KAWAKITA ET AL: "Effect of canarypox virus (ALVAC)-mediated cytokine expression on murine prostate tumor growth", JOURNAL OF THE NATIONAL CANCER INSTITUTE, vol. 89, no. 6, 19 March 1997 (1997-03-19), pages 428 - 436, XP002062563 *
PAOLETTI E ET AL: "IMMUNOTHERAPEUTIC STRATEGIES FOR CANCER USING POXVIRUS VECTORS", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, vol. 690, 12 August 1993 (1993-08-12), pages 292 - 300, XP002042659 *
SEDLACEK H H: "VACCINATION FOR TREATMENT OF TUMORS: A CRITICAL COMMENT", CRITICAL REVIEWS IN ONCOGENESIS, vol. 5, no. 6, 1994, pages 555 - 587, XP000198151 *
SIXTH INTERNATIONAL CONFERENCE ON GENE THERAPY OF CANCER, 2 November 1997 (1997-11-02) - 22 November 1997 (1997-11-22), SAN DIEGO,CALIFORNIA,USA, XP002062564 *

Also Published As

Publication number Publication date
WO1998015635A2 (en) 1998-04-16
AU4448597A (en) 1998-05-05

Similar Documents

Publication Publication Date Title
WO2000055345A3 (en) Therapy of cancer by insect cells containing recombinant baculovirus encoding genes
MY101852A (en) Tumor necrosis factor, methods for its preparation, containing it, dna encoding it and assay method using such dna.
DK0835133T3 (en) Recombinant smallpox virus rabies and combination preparations and their uses
NL990033I2 (en) Tumor necrosis factor, methods of preparing it, compositions containing it, DNA encoding it, and test methods with solid DNA.
IL144371A0 (en) Her-2/neu fusion proteins
WO1995030761A3 (en) Methods of in vivo gene delivery
WO2002012341A3 (en) Her-2/neu fusion proteins
EP1217891A4 (en) Therapeutic methods and compositions using viruses of the recombinant paramyxoviridae family
WO1999047674A3 (en) Compounds and methods for therapy and diagnosis of lung cancer
WO2000061612A3 (en) Compounds and methods for therapy and diagnosis of lung cancer
DE69233186D1 (en) KARCINOEMBRYONAL ANTIGENT EXPECTING RECOMBINANT VIRUSES AND METHODS OF USE
EP0961831A4 (en) Human endokine alpha
WO2003039458A3 (en) TREATMENT OF HUMAN CANCER WITH ADENOVIRAL VECTOR EXPRESSING TNF-α
FI973309A0 (en) Method for preparing a recombinant DNA adenovirus genome
CA2234263A1 (en) Pharmaceutical composition for treating papillomavirus tumours and infection
GB9922361D0 (en) Generating an immune response to an antigen
WO1998015635A3 (en) Treatment of cancer using a recombinant poxvirus containing a nucleic acid sequence encoding a cytokine
EP0811687A3 (en) Polypeptides having l-asparaginase activity
WO2000025827A3 (en) Dna molecules encoding muc-1 and use thereof in tumor vaccination
WO2002094859A3 (en) Mage-a1 peptides for treating or preventing cancer
EP1731611A3 (en) Eimeria hydrophilic polypeptides as vaccines
WO2001004318A3 (en) Myxoma virus genes for immune modulation
WO1998024912A3 (en) Recombinant plague vaccine
WO2001024832A3 (en) Pharmaceutical composition for treating and preventing human tumors, which express the tumor antigen mucin and/or the carcinoembryonic antigen (cea), and the use thereof
RU2005125608A (en) VACCINE BASED ON MUCIN MUC-1 EPITHELIAL CELLS

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1998516022

Format of ref document f/p: F

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: CA

122 Ep: pct application non-entry in european phase
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载